A clinical trial published in the Journal of Affective Disorders in 2026 shows that a single subanesthetic intravenous infusion of ketamine triggers an absolute increase in morning waking cortisol levels 24 hours post-treatment in adults with major depressive disorder and active suicidal ideation. This hormonal surge, which rose from 0.42 to 0.80 on a normalized scale, coincides with ketamine's peak clinical effects. While the rise in cortisol has a small-to-medium correlation with reduced suicidal thoughts, the exact therapeutic mechanism remains uncertain.
Ketamine's rapid anti-suicidal effects
▪The clinical trial found that the increase in morning waking cortisol levels 24 hours after ketamine treatment did not correlate with changes in overall depression severity.
▪The clinical trial found a small-to-medium correlation between increased waking cortisol and decreased suicidal thoughts 24 hours after ketamine treatment, though this correlation did not reach conventional statistical significance.
▪Ketamine can rapidly reduce suicidal ideation and major depression symptoms within hours of administration, whereas traditional antidepressant medications typically require several weeks to show meaningful improvement.
Morning cortisol surge mechanism
▪Researchers suggest that a temporary, moderate rise in morning cortisol triggered by ketamine may help reset the brain's stress-response system, creating a biological buffer that enhances stress resilience.
▪Cortisol is a primary stress hormone produced by the adrenal glands that naturally peaks in the early morning, with an additional spike known as the cortisol awakening response occurring within 30 minutes of waking.
▪Severe depression is frequently associated with a dysregulated stress-response system, or hypothalamic-pituitary-adrenal axis, which often leads to abnormal morning cortisol patterns in affected individuals.
Brain neuroplasticity stimulation
▪Ketamine blocks NMDA receptors in the brain, boosting levels of the neurotransmitter glutamate and stimulating neuroplasticity to encourage the growth of new synapses and neural connections.
▪A July 2026 study in Molecular Psychiatry found that rapid-acting antidepressants, including ketamine, LSD, and psilocybin, converge on downstream neuroimmune pathways, specifically IL-7 and IL-15 signaling.
Clinical trial results
▪The clinical trial of 80 adults with major depressive disorder and active suicidal ideation compared a 40-minute infusion of 0.5 mg/kg ketamine against a control sedative, midazolam, at 0.02 mg/kg.
▪In the clinical trial, the ketamine group's normalized waking cortisol rose from 0.42 to 0.80 after 24 hours, while the midazolam control group's levels shifted from 0.97 to 0.77.
▪A clinical trial published in the Journal of Affective Disorders in 2026 found that a single subanesthetic intravenous infusion of ketamine increases morning waking cortisol levels 24 hours post-treatment.
Ketamine overdose concerns
▪The National Drug Early Warning System identified 71,924 nonfatal emergency medical services encounters involving suspected ketamine overdoses nationwide in the United States between January 2023 and June 2026.
▪In June 2026, the U.S. Food and Drug Administration issued warning letters to 14 internet marketers selling unapproved or misbranded ketamine products.
▪Heavy recreational ketamine use is associated with cognitive impairment, persistent dissociative symptoms, severe abdominal pain known as K-cramps, liver or biliary disease, and permanent bladder damage from ketamine-associated cystitis.
Depression treatment paradigm shift
▪The global ketamine clinic market was valued at approximately USD 1.44 billion in 2025 and is projected to reach USD 3.03 billion by 2032.
▪In 2000, John Krystal and Yale University colleagues first reported that a subanesthetic dose of ketamine could rapidly reduce symptoms of major depression and treatment-resistant depression.
▪The U.S. Food and Drug Administration approved esketamine nasal spray, marketed as Spravato, in 2019 for treatment-resistant depression and major depression with acute suicidal ideation.
Story comments
Loading comments…